Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Human SCG3 Antibody (SAA1746)

Catalog #:   RHJ98001 Specific References (20) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: ELISA
Accession: Q8WXD2
Overview

Catalog No.

RHJ98001

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

SgIII, Secretogranin-3, SCG3, Secretogranin III

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q8WXD2

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1746

Data Image
References

Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody., PMID:39333408

Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy., PMID:39273454

Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease., PMID:38589621

Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice., PMID:37509549

Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy., PMID:37445707

Inhibitory effect of anti-Scg3 on corneal neovascularization: a preliminary study., PMID:36443679

Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy., PMID:35468689

Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization., PMID:35038348

Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy., PMID:35008775

Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy., PMID:35006382

Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization., PMID:34918375

Novel Insight in Idiopathic Normal Pressure Hydrocephalus (iNPH) Biomarker Discovery in CSF., PMID:34360799

TRPV1, TRPA1, and TRPM8 are expressed in axon terminals in the cornea: TRPV1 axons contain CGRP and secretogranin II; TRPA1 axons contain secretogranin 3., PMID:32863706

TRPV1, TRPA1, and TRPM8 are expressed in axon terminals in the cornea: TRPV1 axons contain CGRP and secretogranin II; TRPA1 axons contain secretogranin 3., PMID:38860239

Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety., PMID:30644010

Secretogranin III as a novel target for the therapy of choroidal neovascularization., PMID:30633921

Secretogranin III promotes angiogenesis through MEK/ERK signaling pathway., PMID:29154827

Secretogranin III: a diabetic retinopathy-selective angiogenic factor., PMID:28856381

Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy., PMID:28330905

Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck., PMID:19567214

Datasheet
$ 328
Product specifications
100 μg 328 1 mg 1640

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human SCG3 Antibody (SAA1746) [RHJ98001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only